"Schizophrenia is one of the major debilitating diseases. This is not a disease where patients will recover in a week or two. This is a lifelong treatment — a management, rather than a cure."
Dr. Laxminarayan Bhat didn't stumble into psychiatry. He chose it deliberately, at a moment when the rest of the industry was moving away. In the mid-2000s, as oncology captured most of the venture capital and scientific attention, Lax saw an enormous unmet need hiding in plain sight: 24 million people globally with schizophrenia, every approved drug optimized for the same six-week window of acute stabilization, and a field that had convinced itself the targets were the problem.
He believed the targets weren't the problem. The off-targets were.
What followed was 20 years of translational chemistry — designing bileroxazine from scratch to address not just positive symptoms, but the full spectrum of what schizophrenia actually does to a person over a lifetime: negative symptoms, cognitive impairment, and the neuroinflammation that amplifies everything else. The result is a drug with a side effect profile comparable to placebo and a one-year discontinuation rate of 35% — roughly half of what standard-of-care produces.
The Problem With 40 Years of Antipsychotics
Every antipsychotic approved in the last four decades uses the same primary endpoint: PANSS reduction in hospitalized patients over four to six weeks. That means clinical trials are designed to measure one thing — whether acute hallucinations stabilize. It's a reasonable short-term goal. But schizophrenia onset typically hits in the teenage years, and most patients will live with the disease for the next 50 to 60 years.
The drugs approved for acute stabilization are the drugs patients then stay on indefinitely. And they were never designed for that job. Negative symptoms — flat affect, social withdrawal, anhedonia — go largely untreated. Cognitive impairment, which determines whether patients can hold jobs and maintain relationships, isn't addressed. And the neuroinflammation that affects every single patient at varying degrees compounds everything, driving side effects and accelerating the disease itself.
The result: 60 to 70% of patients discontinue their medication within a year. That's not a compliance problem. That's a drug problem.
What Makes Bileroxazine Different
Bileroxazine's differentiation starts with how it was designed. Rather than optimizing for acute dopamine-blocking efficacy and tolerating whatever else came along, Dr. Bhat started with a clear theory of what schizophrenia actually requires over a lifetime.
The molecule targets serotonin-dopamine signaling — the accepted primary mechanism — but adds potent 5-HT2B activity, which targets neuroinflammation at the microglial level. That 5-HT2B selectivity is three to four times more potent than the drug's dopamine activity. Addressing neuroinflammation simultaneously enhances efficacy across symptom domains and eliminates the off-target side effects that cause patients to stop taking their medication.
The pharmacokinetics reflect the same logic. Most antipsychotics are cleared by CYP2D6 or CYP1A2 — enzymes that vary widely across individuals and create drug-drug interaction risks. Bileroxazine was designed to avoid those pathways. It's absorbed at ~75%, dosed once daily, and cleared through major expressed enzymes — all deliberate engineering choices for a drug meant to be taken for life.
The Discontinuation Rate as a North Star
Dr. Bhat uses one metric to cut through the noise: discontinuation rate. "If a treatment isn't efficacious, or is having a lot of side effects — or both — patients discontinue." It's the single number that captures everything clinical trials try to measure separately.
In Reviva's acute trial, discontinuation was 16% — lower than placebo. In the one-year long-term study, it was 35%. Standard of care in comparable one-year trials runs 60 to 70%. That gap is what broad-spectrum efficacy and a benign side effect profile produces when designed together from the start.
Motor side effects — one of the irreversible consequences of some antipsychotics — were clinically insignificant over a full year of treatment. Prolactin dysregulation, which causes sexual side effects and drives many patients off their medication, was comparable to placebo. Secondary endpoints — negative symptoms, social cognition, functional outcomes — showed robust improvement across two large trials with 400+ patients. Not just the primary endpoint. Everything.
Biomarkers, Precision Psychiatry, and Commercial Reality
Reviva became the first company in schizophrenia to use both blood-based and digital biomarkers in its trials. The digital biomarker was vocal — schizophrenia patients have a measurable signature in how they speak that machine learning can detect at millisecond precision. In the long-term open-label study, this provided objective evidence of negative symptom improvement independent of clinician assessment.
That biomarker capability led to a meaningful clinical insight: in the double-blind study, they identified 229 out of 411 patients with high negative symptom severity using the vocal biomarker, randomized within that group, and saw almost double the efficacy on negative symptom endpoints. Biomarker enrichment works.
On precision psychiatry, Dr. Bhat is direct about commercial limits. Building a precision medicine approach for schizophrenia — requiring an approved patient identification tool, a narrowly defined patient population, and $500M+ in development costs — isn't economically viable today. The better bet is a broad-spectrum drug that works well for most patients. That's bileroxazine, and the NDA is coming.
What You'll Learn
- Why current antipsychotics leave 50% of patient needs unmet — and what "off-target" pharmacology has to do with it
- How bileroxazine's absorption and metabolism profile was engineered for lifelong use
- The significance of achieving a 35% discontinuation rate versus 60–70% with existing treatments
- Why targeting positive, negative, and cognitive symptom domains simultaneously is critical for long-term outcomes
- How digital vocal biomarkers were used to enrich negative symptom cohorts in clinical trials
- The practical limits of precision psychiatry and why commercial viability shapes drug development strategy
- What's next for Reviva as they approach NDA submission
Episode Highlights
- [00:00] Intro: Meeting Dr. Bhat of Reviva Pharmaceuticals
- [01:24] From Scientist to CEO: Dr. Bhat's 25-Year Journey in Drug Development
- [03:46] Understanding Schizophrenia: A Lifelong Management Challenge
- [09:51] Breaking Down Clinical Trial Success: Superior Efficacy and Safety Profile
- [15:05] The Discovery Story: Origins of a Novel Schizophrenia Treatment
- [24:52] Evolution of Schizophrenia Drug Development: New Approaches vs Traditional Methods
- [30:50] Biomarkers and Precision Medicine in Psychiatric Treatment
- [36:57] Looking Ahead: Next Steps for Reviva's Breakthrough Drug
